DiI (DiIC18(3)) Membrane Probe Guide

2026-09-11

DiI (DiIC18(3)) is a lipophilic orange fluorescent probe for visualizing plasma membranes in live or fixed cells and tissues. It is useful for membrane movement, neuronal tracing, migration, and adhesion workflows, but it is water-insoluble and should not be treated as an organelle-selective or detergent-insensitive stain.

CDELNs Relieve Testicular Injury via Sertoli Cells

2026-09-10

This preprint identifies Cistanche deserticola exosome-like nanovesicles (CDELNs) as a plant-derived intervention for cyclophosphamide-induced testicular injury. The study links preferential Sertoli-cell uptake to heparan sulfate proteoglycans and proposes a miR159b-3p–P21–CDK1 mechanism for relieving cell-cycle arrest.

BOP Reagent Workflows for Peptide Synthesis

2026-09-10

BOP reagent enables practical carboxyl group activation for amide bond formation, phenyl ester preparation, and modular peptide or conjugate synthesis. This guide translates its solution handling and coupling chemistry into reproducible workflows, while showing how the reference study can inspire assay controls without implying that BOP was used in that publication.

GSK126: EZH2 Inhibitor Workflow Guide

2026-09-09

GSK126 provides a selective way to connect EZH2/PRC2 catalytic activity with H3K27me3 loss, gene reactivation, and phenotype in cancer and stem-cell assays. This practical guide covers dose planning, orthogonal readouts, translational applications, and troubleshooting for reproducible epigenetic experiments.

AG-126: Practical ERK1/2 Inhibition Workflows

2026-09-09

AG-126 enables time- and concentration-controlled testing of ERK1/2 signaling in inflammatory, neuronal, and cell-based assays. This guide connects validated PCW inflammation evidence with a carefully bounded experimental strategy for studying ERK contributions to D2-MSN activity and repetitive-behavior phenotypes.

Spirocyclic POM Analogues Target MmpL3 in TB

2026-09-08

The 2024 Bioorganic Chemistry study developed spirocyclic phenyl oxazole methyl analogues and identified compound 5c as a potent inhibitor of Mycobacterium tuberculosis growth, including activity against drug-resistant clinical isolates. Phenotypic screening, susceptibility testing, cytotoxicity and ADME/PK assessment, spontaneous mutant generation, and docking collectively supported MmpL3 as the biological target.

Poria cocos, NRF2, and Ferroptosis in ALD

2026-09-08

SHC-1 Inhibition and CFTR Surface Trafficking

2026-09-07

A 2026 study shows that MAPK/SHC-1-dependent internalization of CFTR is conserved across airway and intestinal epithelial models, but pharmacological SHC-1 inhibition increases surface CFTR selectively in CFBE cells. The work highlights a key limitation of model-specific trafficking assays: greater CFTR abundance at the plasma membrane may accompany broader changes in membrane protein distribution rather than a selective correction of CFTR localization.

Simvastatin (Zocor): From Lipid Biology to Translation

2026-09-07

Simvastatin is more than a cholesterol synthesis inhibitor: it is a context-sensitive probe whose prodrug activation, lipid biology, and concentration-dependent phenotypes must be aligned with the biology of each model. This thought-leadership article connects Simvastatin (Zocor) research in hyperlipidemia and hepatic cancer with emerging insights into translation control, stress granules, and STMN2 vulnerability in neurodegeneration—while clearly separating evidence from hypothesis.

Pexmetinib (ARRY-614) Assay Guide

2026-09-05

This scenario-based guide explains how Pexmetinib (ARRY-614), SKU B6012, can support controlled studies of p38 MAPK and Tie2 signaling while avoiding common solvent, endpoint, and interpretation errors. It connects reported biochemical and cellular potency with practical handling guidance for cytokine, viability, proliferation, and cytotoxicity workflows.

Tropifexor (LJN452): A Translational FXR Strategy

2026-09-04

Tropifexor (LJN452) offers a precision pharmacology approach for connecting FXR activation with bile acid biology, metabolic disease research, and intestinal epithelial barrier function research. This thought-leadership guide shows how to position the compound within translational workflows, interpret liver and gut endpoints, and avoid overextending preclinical evidence.

UTP Solution (100 mM): Reliable RNA Workflows

2026-09-04

Learn how UTP Solution (100 mM), SKU K1048, can reduce controllable variability in in vitro transcription, RNA amplification, and siRNA synthesis workflows that support cell-based research. This scenario-driven guide separates documented product specifications from application-level validation and connects nucleotide quality with interpretation of complex gene-expression assays.

From Immune Rejuvenation to mRNA Strategy

2026-09-03

A translational framework linking immune-aging biology in Alzheimer’s disease models with selective, reproducible mRNA workflows using Oligo (dT) 25 Beads.

Risedronate Sodium: From Mechanism to Assay

2026-09-02

Risedronate Sodium is more than an FPP synthase inhibitor: it is a translational probe linking osteoclast biology, formulation science, and clinically meaningful bone endpoints. This guide converts the RISOTTO trial into practical decisions for bone and pulmonary research assays.

Cediranib (AZD2171) for Angiogenesis Assays

2026-09-02

Cediranib (AZD2171) combines sub-nanomolar VEGFR-2 activity with a workflow-friendly mechanism for dissecting angiogenesis, endothelial signaling, and tumor-cell responses. Pairing phospho-Akt measurements with separate proliferation and death assays prevents misleading conclusions from a single viability endpoint.